Hypoglycemia is observed when GLP-1 receptor agonists are combined with insulin therapy, so clinicians and patients have to be attentive to reducing insulin dosages given the weight loss induced by GLP-1 receptor agonists
We believe ongoing support is essential for successful and sustainable weight loss
Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-b Activation
The cardiovascular safety profiles of GLP-1RAs are favorable, with no significant increase in the incidence of acute pancreatitis or pancreatic cancer reported.14 However, their use is associated with a higher frequency of gastrointestinal adverse events, such as nausea, vomiting, and diarrhea.15 GLP-1RAs are considered safe in patients with chronic kidney disease and effective in reducing the risk of severe hypoglycemia.16 In individuals with established cardiovascular diseases, GLP-1RAs have been shown to significantly lower the risk of major adverse cardiovascular events.15 Nevertheless, limited cardiovascular and renal outcome data for certain agents, such as oral semaglutide, have constrained their broader clinical application.17 In the context of post-transplant diabetes, GLP-1RAs exhibit efficacy and safety profiles comparable to those observed in non-transplant populations.18 This review was conducted through comprehensive searches of electronic databases, including Web of Science and PubMed, using a full-text search strategy
Pfeffer MA, Claggett B, Diaz R, et al
